Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03514017
Title Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.